OPRX - OptimizeRx Q4 top line miss lackluster 2023 revenue guidance drives shares down 19%

March, 08 2023 05:20 PM OptimizeRx Corporation

2023-03-08 17:20:45 ET

OptimizeRx ( NASDAQ: OPRX ) is down ~19% in after-hours trading after its Q4 2022 revenue results missed expectations and its 2023 revenue growth guidance came in well below consensus.
In 2023, the company said it expects net revenues to increase at least 10% year over year. Consensus is expecting 20.5% year-over-year growth.
In Q1 2023, OptimizeRx ( OPRX ) is expecting revenue between $11.5M and $13M. For the year, the consensus estimate is $77.8M.
In Q4 2022, OptimizeRx ( OPRX ) swung to a net loss ~$325.8K from a net income of ~$623.5K in the year-ago period ($0.25 non-GAAP diluted per share vs $0.22).
The company ended 2022 with ~$18.2M in cash and cash equivalents compared to ~$84.7M at the end of 2021.
Seeking Alpha's Quant Rating views OptimizeRx ( OPRX ) as a hold with high marks for growth and profitability .

For further details see: